Zymeworks Expands Commercial Team and Creates New R&D Role
February 09 2021 - 4:30PM
Business Wire
- James Priour promoted to Chief Commercial Officer, added to
Zymeworks’ Executive Committee
- John Babcook recognized as Distinguished Fellow
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
that James Priour, former Senior Vice President, Commercial, has
been promoted to Chief Commercial Officer and named to the
Company’s Executive Committee. The Commercial team also recently
expanded its leadership with the addition of Manny Duenas as Vice
President, Global Value & Access. Zymeworks also announced that
John Babcook, former head of Discovery Research, will move into a
newly created Distinguished Fellow role. Senior Vice President of
Research Guowei Fang, Ph.D. will take on leadership of Discovery
Research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210209006171/en/
James Priour, Zymeworks Chief Commercial
Officer (Photo: Business Wire)
“James’ promotion to Chief Commercial Officer goes hand-in-hand
with the success of our lead clinical candidate, zanidatamab, and
its progression toward potential commercialization,” said Ali
Tehrani, Ph.D., President and CEO at Zymeworks. “Zymeworks’
commercial organization is growing under James’ leadership and is
focused on achieving rapid and broad access to our potential
medicines for patients around the world who need them.”
Zymeworks is also recognizing the tremendous career
accomplishments and future ambitions of John Babcook through the
creation of a new position: Distinguished Fellow. In this role John
will expand his efforts as a scientific liaison for Zymeworks,
leveraging his wide-ranging network to identify new opportunities
for the Company. John holds 14 patents and is the recipient of
LifeSciences British Columbia’s Innovation and Achievement Award
and the Dr. Don Rix Award for Lifetime Achievement.
“John’s illustrious career spans over 25 years and has been
characterized by his commitment to making the world a better place
through science,” said Tony Polverino, EVP, Early Development and
Chief Scientific Officer at Zymeworks. “John has tenaciously worked
on innovative approaches to identify, characterize and develop
antibody-based therapies that have the potential to transform
patients’ lives. His broad experience in drug discovery and
development will enable him to identify early-stage scientific
concepts that could lead to important therapeutic breakthroughs for
patients.”
About Zymeworks Inc. Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the development of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25),
is a novel Azymetric™ bispecific antibody which has been granted
Breakthrough Therapy designation by the FDA and is currently
enrolling in a pivotal clinical trial for refractory HER2-amplified
biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2
clinical trials for HER2-expressing gastroesophageal and breast
cancers. Zymeworks’ second clinical candidate, ZW49, is a novel
bispecific HER2-targeting antibody-drug conjugate currently in
Phase 1 clinical development and combines the unique design and
antibody framework of zanidatamab with Zymeworks’ proprietary
ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
Zymeworks Cautionary Note Regarding Zymeworks’
Forward-Looking Statements This press release includes
“forward-looking statements” within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and “forward-looking
information” within the meaning of Canadian securities laws, or
collectively, forward-looking statements. Forward-looking
statements in this news release include statements that relate to
Zymeworks’ expectations regarding the progression of zanidatamab
towards potential commercialization, growth of its commercial
organization, Mr. Babcook’s identification of new opportunities for
Zymeworks, and other information that is not historical
information. When used herein, words and phrases such as “will”,
“believe”, “potential to”, and similar expressions are intended to
identify forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance, or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions, including assumptions regarding the efficacy of
zanidatamab, ZW49, and Zymeworks’ therapeutic platforms, and
Zymeworks’ ability to maintain its partnership arrangements.
Zymeworks believes there is a reasonable basis for its expectations
and beliefs, but they are inherently uncertain. Zymeworks may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
factors, including, without limitation, market conditions and the
factors described under “Risk Factors” in Zymeworks’ Quarterly
Report on Form 10-Q for its fiscal quarter ended September 30, 2020
(a copy of which may be obtained at www.sec.gov and at
www.sedar.com). Consequently, forward-looking statements should be
regarded solely as Zymeworks’ current plans, estimates, and
beliefs. You should not place undue reliance on forward-looking
statements. Zymeworks cannot guarantee future results, events,
levels of activity, performance, or achievements. Zymeworks does
not undertake and specifically declines any obligation to update,
republish, or revise any forward-looking statements to reflect new
information, future events, or circumstances, or to reflect the
occurrences of unanticipated events, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209006171/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Mary Klem (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024